OncoCyte Corporation (OCX)
Company Description
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally.
The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Country | United States |
Founded | 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 75 |
CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California 92618 United States | |
Phone | 949-409-7600 |
Website | oncocyte.com |
Stock Details
Ticker Symbol | OCX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001642380 |
CUSIP Number | 68235C107 |
ISIN Number | US68235C2061 |
Employer ID | 27-1041563 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Joshua Riggs | President, Chief Executive Officer and Director |
James Liu | Senior Director, Controller, Principal Accounting Officer and Interim Principal Financial Officer |
Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
Peter Hong | Vice President, General Counsel and Secretary |
Yuh-Min Chiang Ph.D. | Senior Vice President of Research & Development and Product Development |
Sandra O'Donald | Senior Vice President of Business Operations |
Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc. |
Sara Riordan | Director of Medical Education |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 23, 2024 | 8-K | Current Report |
Nov 9, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Oct 10, 2023 | 8-K/A | [Amend] Current report |
Oct 5, 2023 | 8-K | Current Report |
Sep 20, 2023 | 8-K | Current Report |
Aug 28, 2023 | 8-K | Current Report |
Aug 10, 2023 | 10-Q | Quarterly Report |